75 patents
Utility
Methods of Treating Disorders Using CSF1R Inhibitors
28 Dec 23
Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
Filed: 28 Apr 23
Utility
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
19 Dec 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 11 Aug 23
Utility
Compositions of 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA
7 Dec 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 11 Aug 23
Utility
Compositions of 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA
7 Dec 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 11 Aug 23
Utility
Compositions of 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA
7 Dec 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 11 Aug 23
Utility
Compositions of 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA
7 Dec 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 11 Aug 23
Utility
GCN2 and Perk Kinase Inhibitors and Methods of Use Thereof
30 Nov 23
Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
Yu Mi Ahn, Gada Al-Ani, Daniel L. Flynn, Salim Javed, Patrick Kearney, Bertrand LeBourdonnec, Kristen Stoltz, Jeffery Zwicker
Filed: 2 Dec 22
Utility
Methods of treating gastrointestinal stromal tumors
14 Nov 23
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Filed: 30 Dec 22
Utility
Raf Kinase Inhibitors and Methods of Use Thereof
9 Nov 23
Described herein are compounds that are RAF inhibitors and their use in the treatment of disorders such as cancers.
Daniel L. Flynn, Yu Mi Ahn, Lakshminarayana Vogeti, Bertrand Le Bourdonnec
Filed: 9 Dec 22
Utility
Anti-viral activity of VPS34 inhibitors
31 Oct 23
Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor.
Daniel L. Flynn
Filed: 24 Nov 21
Utility
Amorphous kinase inhibitor formulations and methods of use thereof
31 Oct 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 9 May 23
Utility
Aminopyrimidine Amide Autophagy Inhibitors and Methods of Use Thereof
26 Oct 23
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti
Filed: 11 Jan 23
Utility
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
24 Oct 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 6 Mar 23
Utility
Methods of treating gastrointestinal stromal tumors
10 Oct 23
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Jing Wang, Xiaoyan Li
Filed: 6 Oct 22
Utility
CorrectedMethods for Treating Vascular Malformations
7 Sep 23
Daniel L. Flynn, Bryan D. Smith, Miikka Vikkula
Filed: 12 Aug 20
Utility
Amorphous Kinase Inhibitor Formulations and Methods of Use Thereof
31 Aug 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 9 May 23
Utility
Raf Kinase Inhibitors and Methods of Use Thereof
17 Aug 23
Described herein are compounds that are RAF inhibitors and their use in the treatment of disorders such as cancers.
Daniel L. Flynn, Yu Mi Ahn, Lakshminarayana Vogeti, Bertrand Le Bourdonnec
Filed: 9 Dec 22
Utility
Compositions of 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA
29 Jun 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 30 Dec 22
Utility
Compositions of 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA
29 Jun 23
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Filed: 6 Mar 23
Utility
Methods of Treating Gastrointestinal Stromal Tumors
11 May 23
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Filed: 30 Dec 22